Defining the therapeutic algorithm in patients with HR positive breast cancer - United States

Title
Defining the therapeutic algorithm in patients with HR positive breast cancer

Target Audience
The initiative will target oncology clinicians in the US, Germany, Spain, Italy, and France, and specifically those actively involved in the treatment of breast cancer.

Learning Objectives

1. Assess the efficacy and safety of treatment approaches, including antibody-drug conjugates, in the management of patients with HER2+, HER2-Low, and TNBC mBC, with and implications for team-based and shared decision-making globally
2. Apply the most recent evidence-based recommendations when managing patients with HER2+, HER2-Low, and TNBC based on specific patient and tumor characteristics
3. Discuss the most recent evidence -based recommendations, guidelines, and clinical trial presentations on the role of antibody-drug conjugates on the management of patients with HER2+, HER2-Low, and TNBC

Faculty

Francesco Pantano MD, PHD
Campus Biomedico Roma
Rome, Italy

Disclosures of Relevant Financial Relationships

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Francesco Pantano MD, PHD declared receipt of honoraria or consultation fees from AstraZeneca, Novartis, Pfizer, Eli Lilly, Daiichi Sankyo, and Gilead.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hour (0.5 CNE pharmacotherapeutic contact hours).

AcademicCME designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA4008190-0000-24-015-H01-P

Type of Activity: Application

For Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to the CPE Monitor as required. After receipt of a completed activity evaluation form, you will be provided with instructions to have your credit immediately uploaded to the CPE Monitor.

Through an agreement between the American Medical Association and the Union Européenne des Médecins Spécialistes, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits

This e-learning activity: "Defining the therapeutic algorithm in patients with HR positive breast cancer" will be submitted for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME).

Disclosures of Relevant Financial Relationships

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Francesco Pantano declared receipt of honoraria or consultation fees from: Astra Zeneca, Novartis, Pfizer, Lilly, Daiichi Sankyo, Gilead.

Financial Support

This activity has been supported by an independent educational grant from Daiichi Sankyo, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Daiichi Sankyo, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order claim to the maximum amount of credit, participants must complete the following:

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit). 

• CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion. 
• CME and CNE credit will be issued appropriate certificate of completion. 
• Others may request a "certificate of completion".

6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact admin@academiccme.com.

COURSE VIEWING REQUIREMENTS